Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

Moderna and MSD have begun a Phase III study to evaluate mRNA-4157 (V940) in combination with KEYTRUDA to treat non-small cell lung cancer.

Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...

V940 is an investigational individualized neoantigen therapy under development in combination with Keytruda (pembrolizumab) as adjuvant treatment for resectable Stage II, IIIA or IIIB (N2 ...

Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ongoing sluggishness ...